Show simple item record

dc.contributor.authorPascual, J
dc.contributor.authorMacPherson, IR
dc.contributor.authorArmstrong, Anne C
dc.contributor.authorWard, SE
dc.contributor.authorParmar, M
dc.contributor.authorTurner, AJ
dc.contributor.authorBye, H
dc.contributor.authorProszek, P
dc.contributor.authorDodson, A
dc.contributor.authorGarcia-Murillas, I
dc.contributor.authorKing, J
dc.contributor.authorHall, E
dc.contributor.authorFinneran, L
dc.contributor.authorLopez, JS
dc.contributor.authorOkines, AFC
dc.contributor.authorRing, AE
dc.contributor.authorTurner, NC
dc.date.accessioned2019-11-19T16:01:07Z
dc.date.available2019-11-19T16:01:07Z
dc.date.issued2019en
dc.identifier.citationPascual J, MacPherson IR, Armstrong AC, Ward SE, Parmar M, Turner AJ, et al. PIPA: a phase Ib study of ?-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer. J Clin Oncol. 2019;37(15_suppl):1051-.en
dc.identifier.doi10.1200/JCO.2019.37.15_suppl.1051en
dc.identifier.urihttp://hdl.handle.net/10541/622460
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2019.37.15_suppl.1051en
dc.titlePIPA: a phase Ib study of beta-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast canceren
dc.typeMeetings and Proceedingsen
dc.contributor.departmentRoyal Marsden Hospital and The Institute of Cancer Research, Londonen
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record